TECTONIC THERAPEUTIC, INC. Net Income
TECTONIC THERAPEUTIC, INC. (TECX) reported Net Income of -$22.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-06
- TECTONIC THERAPEUTIC, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$22.29M.
- TECTONIC THERAPEUTIC, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$25.24M.
- TECTONIC THERAPEUTIC, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$74.10B.
- TECTONIC THERAPEUTIC, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$19.04M.
- TECTONIC THERAPEUTIC, INC. net income (loss) attributable to parent for fiscal 2022 was -$105.89M.
- TECTONIC THERAPEUTIC, INC. net income (loss) attributable to parent for fiscal 2021 was -$119.13M.
- TECTONIC THERAPEUTIC, INC. net income (loss) attributable to parent for fiscal 2020 was -$119.71M.
- TECTONIC THERAPEUTIC, INC. net income (loss) attributable to parent for fiscal 2019 was -$72.97M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$22.29M 10-Q · filed 2026-08-06 | -$47.53M 10-Q · filed 2026-08-06 | -$74.14B derived: sum of 3 quarters · filed 2026-08-06 | -$74.16B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$25.24M 10-Q · filed 2026-08-06 | -$74.12B derived: sum of 2 quarters · filed 2026-08-06 | -$74.14B derived: sum of 3 quarters · filed 2026-08-06 | -$74.16B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$74.10B derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$74.12B derived: sum of 2 quarters · filed 2026-04-24 | -$74.14B derived: sum of 3 quarters · filed 2026-08-06 | -$74.15B DEF 14A · filed 2026-04-24 | -$74.15M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | -$19.04M 10-Q · filed 2025-11-06 | -$39.02M derived: sum of 2 quarters · filed 2026-08-06 | -$54.92M 10-Q · filed 2025-11-06 | -$57.99B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$19.98M 10-Q · filed 2026-08-06 | -$35.89M 10-Q · filed 2026-08-06 | -$57.97B derived: sum of 3 quarters · filed 2026-08-06 | -$57.99B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$15.91M 10-Q · filed 2026-08-06 | -$57.95B derived: sum of 2 quarters · filed 2026-08-06 | -$57.97B derived: sum of 3 quarters · filed 2026-08-06 | -$57.98B derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2024-12-31 | -$57.94B derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$57.95B derived: sum of 2 quarters · filed 2026-04-24 | -$57.97B derived: sum of 3 quarters · filed 2026-04-24 | -$57.98B DEF 14A · filed 2026-04-24 | -$57.98M 10-K · filed 2025-03-20 | |||
| 2024-09-30 | -$17.72M 10-Q · filed 2025-11-06 | -$30.39M derived: sum of 2 quarters · filed 2025-11-06 | -$45.61M 10-Q · filed 2025-11-06 | -$42.83B derived: sum of 4 quarters · filed 2026-04-24 | ||||
| 2024-06-30 | -$12.67M 10-Q · filed 2025-11-06 | -$27.89M 10-Q · filed 2025-08-07 | -$42.82B derived: sum of 3 quarters · filed 2026-04-24 | -$42.83B derived: sum of 4 quarters · filed 2026-04-24 | ||||
| 2024-03-31 | -$15.22M 10-Q · filed 2025-11-06 | -$6.81M 10-Q · filed 2024-05-09 | -$42.80B derived: sum of 2 quarters · filed 2026-04-24 | -$42.81B derived: sum of 3 quarters · filed 2026-04-24 | -$42.82B derived: sum of 4 quarters · filed 2026-04-24 | |||
| 2023-12-31 | -$42.79B derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-24 | -$42.80B derived: sum of 2 quarters · filed 2026-04-24 | -$42.81B derived: sum of 3 quarters · filed 2026-04-24 | -$42.82B DEF 14A · filed 2026-04-24 | $12.16M 10-K · filed 2024-03-14 | |||
| 2023-09-30 | -$10.05M 10-Q · filed 2024-11-12 | -$21.58M 10-Q · filed 2023-11-09 | -$20.51M derived: sum of 2 quarters · filed 2024-11-12 | -$34.95M 10-Q · filed 2024-11-12 | $20.94M 10-Q · filed 2023-11-09 | -$59.99M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$10.46M 10-Q · filed 2024-11-12 | $67.48M 10-Q · filed 2023-08-10 | -$24.90M 10-Q · filed 2024-08-14 | $42.52M 10-Q · filed 2023-08-10 | -$49.93M derived: sum of 3 quarters · filed 2024-11-12 | -$72.90M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-03-31 | -$14.45M 10-Q · filed 2024-11-12 | -$24.96M 10-Q · filed 2023-05-11 | -$39.48M derived: sum of 2 quarters · filed 2024-11-12 | -$62.45M derived: sum of 3 quarters · filed 2024-11-12 | -$90.50M derived: sum of 4 quarters · filed 2024-11-12 | |||
| 2022-12-31 | -$25.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$48.00M derived: sum of 2 quarters · filed 2024-03-14 | -$76.06M derived: sum of 3 quarters · filed 2024-03-14 | -$105.89M 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | -$22.97M 10-Q · filed 2023-11-09 | -$51.02M derived: sum of 2 quarters · filed 2023-11-09 | -$80.86M 10-Q · filed 2023-11-09 | -$109.08M derived: sum of 4 quarters · filed 2023-11-09 | ||||
| 2022-06-30 | -$28.05M 10-Q · filed 2023-08-10 | -$57.89M 10-Q · filed 2023-08-10 | -$86.11M derived: sum of 3 quarters · filed 2023-08-10 | -$118.73M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$29.83M 10-Q · filed 2023-05-11 | -$58.06M derived: sum of 2 quarters · filed 2023-05-11 | -$90.67M derived: sum of 3 quarters · filed 2023-05-11 | -$122.06M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$28.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$60.84M derived: sum of 2 quarters · filed 2023-03-23 | -$92.23M derived: sum of 3 quarters · filed 2023-03-23 | -$119.13M 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | -$32.61M 10-Q · filed 2022-11-08 | -$64.00M derived: sum of 2 quarters · filed 2022-11-08 | -$90.90M 10-Q · filed 2022-11-08 | -$119.03M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | -$31.39M 10-Q · filed 2022-08-09 | -$58.29M 10-Q · filed 2022-08-09 | -$86.42M derived: sum of 3 quarters · filed 2022-08-09 | -$123.20M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | -$26.90M 10-Q · filed 2022-05-10 | -$55.03M derived: sum of 2 quarters · filed 2022-05-10 | -$91.81M derived: sum of 3 quarters · filed 2022-05-10 | -$120.64M derived: sum of 4 quarters · filed 2022-05-10 | ||||
| 2020-12-31 | -$28.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$64.91M derived: sum of 2 quarters · filed 2022-03-17 | -$93.74M derived: sum of 3 quarters · filed 2022-03-17 | -$119.71M 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | -$36.78M 10-Q · filed 2021-11-04 | -$65.61M derived: sum of 2 quarters · filed 2021-11-04 | -$91.58M 10-Q · filed 2021-11-04 | -$114.24M derived: sum of 4 quarters · filed 2021-11-04 | ||||
| 2020-06-30 | -$28.83M 10-Q · filed 2021-08-05 | -$54.80M 10-Q · filed 2021-08-05 | -$77.46M derived: sum of 3 quarters · filed 2021-08-05 | -$94.61M derived: sum of 4 quarters · filed 2021-08-05 | ||||
| 2020-03-31 | -$25.97M 10-Q · filed 2021-05-13 | -$48.63M derived: sum of 2 quarters · filed 2021-05-13 | -$65.78M derived: sum of 3 quarters · filed 2021-05-13 | -$81.83M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | -$22.66M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$39.81M derived: sum of 2 quarters · filed 2021-03-18 | -$55.86M derived: sum of 3 quarters · filed 2021-03-18 | -$72.97M 10-K · filed 2021-03-18 | ||||
| 2019-09-30 | -$17.14M 10-Q · filed 2020-11-05 | -$33.20M derived: sum of 2 quarters · filed 2020-11-05 | -$50.30M 10-Q · filed 2020-11-05 | -$66.32M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | -$16.05M 10-Q · filed 2020-11-05 | -$33.16M 10-Q · filed 2020-08-06 | -$49.18M derived: sum of 3 quarters · filed 2020-11-05 | -$60.77M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-03-31 | -$17.10M 10-Q · filed 2020-11-05 | -$33.12M derived: sum of 2 quarters · filed 2020-11-05 | -$44.72M derived: sum of 3 quarters · filed 2020-11-05 | -$55.22M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2018-12-31 | -$16.02M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | -$27.61M derived: sum of 2 quarters · filed 2020-03-16 | -$38.12M derived: sum of 3 quarters · filed 2020-03-16 | -$46.36M 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | -$11.59M 10-Q · filed 2019-11-07 | -$22.10M derived: sum of 2 quarters · filed 2019-11-07 | -$30.34M 10-Q · filed 2019-11-07 | -$37.94M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | -$10.51M 10-Q · filed 2019-11-07 | -$18.75M 10-Q · filed 2019-08-08 | -$26.34M derived: sum of 3 quarters · filed 2019-11-07 | -$32.79M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-03-31 | -$8.24M 10-Q · filed 2019-11-07 | -$15.84M derived: sum of 2 quarters · filed 2019-11-07 | -$22.28M derived: sum of 3 quarters · filed 2019-11-07 | -$24.81M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2017-12-31 | -$7.60M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-25 | -$14.04M derived: sum of 2 quarters · filed 2019-03-25 | -$16.57M derived: sum of 3 quarters · filed 2019-03-25 | -$18.65M 10-K · filed 2019-03-25 | ||||
| 2017-09-30 | -$6.44M 10-Q · filed 2018-11-13 | -$8.97M derived: sum of 2 quarters · filed 2018-11-13 | -$11.05M 10-Q · filed 2018-11-13 | |||||
| 2017-06-30 | -$2.53M 10-Q · filed 2018-08-09 | -$4.61M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |